Qualified applicants must live in or near New Orleans, LA. Myriad is looking for top sales talent and individuals who are passionate about improving patients' lives. As a Sales Executive, you will actively expand the business while providing support to existing business within our focused market of practices. This is not just another sales job, rather a unique opportunity to be on the leading edge of an industry defining product. At Myriad, you will have the chance to build a career with an organization that defines its culture by putting patients and people first. Asan Account Executivefor Myriad Urology, you will focus ondeveloping business for MyriadUrology,promotingProlaris, BRACAnalysis CDx and MyRiskto hospitals, hospital systems, large practices and oncology-specific institutions.TheProlaris test from Myriad Genetics is the only biomarker test on the market with an Active Surveillance Threshold that has been clinically validated and proven to work in initially untreated patients. Job Responsibilities and Competencies * Increase the Prolaris test orders and promote and increase MyRisk and BRACANalysis CDx test orders; identify and implement an action plan to drive growth * Target and focus sales efforts on urologists, urologic oncologists, and affiliated pathologists * Grow weekly order volumes by teaching, tailoring, and taking control of customer conversations in community, large group, and academic practice settings * Offer unique perspectives to customers, drive two-way communication with targeted physicians, learn and understand practice value and economic drivers and influence customers to adopt a different approach to prostate cancer risk assessment and treatment The clinical challenge facing physicians and their patients newly diagnosed with prostate cancer is whether to choose definitive therapy such as surgery or radiation, which have potentially significant complications, or to monitor the patient's cancer through active surveillance or watchful waiting. Unfortunately, existing clinical parameters (PSA, Gleason score, and stage) used to make this difficult decision do not adequately predict which cancers are indolent or aggressive, resulting in both under treatment and overtreatment of men with prostate cancer. Myriad Genetic Laboratories discovered and validated Prolaris, a novel RNA expression-based prognostic test, to fulfil this pressing unmet clinical need. Prolaris directly measures tumor cell growth characteristics in order to stratify patients with localized prostate cancer according to disease aggressiveness. More than 700 urologists and urologic oncologists in the U.S. have used the test to identify both low-risk patients who may be monitored through active surveillance or watchful waiting, as well as high-risk patients who may benefit from earlier definitive treatment. Prolaris is the only molecular test in its category with 6 peer-reviewed publications supporting its clinical validity and two forthcoming publications that demonstrate significant change in treatment... For full info follow application link.

We recognize that our people are our strength and the diverse talents they bring to our global workforce are directly linked to our success. We are an equal opportunity employer and place a high value on diversity and inclusion at our company. In hiring and all other employment decisions, we prohibit discrimination and harassment on the basis of any protected characteristic, including race, religion, color, national origin, gender, sexual orientation, gender identity, gender expression, age, marital or veteran status, pregnancy or disability, or any other basis protected under applicable law. In accordance with applicable law, we make reasonable accommodations for applicants' and employees' religious practices and beliefs, as well as any mental health or physical disability needs.

#LifeSciences